JP6548897B2 - 同種異系細胞の医療用途の誘導のための方法及び組成物並びに治療的利用 - Google Patents

同種異系細胞の医療用途の誘導のための方法及び組成物並びに治療的利用 Download PDF

Info

Publication number
JP6548897B2
JP6548897B2 JP2014550544A JP2014550544A JP6548897B2 JP 6548897 B2 JP6548897 B2 JP 6548897B2 JP 2014550544 A JP2014550544 A JP 2014550544A JP 2014550544 A JP2014550544 A JP 2014550544A JP 6548897 B2 JP6548897 B2 JP 6548897B2
Authority
JP
Japan
Prior art keywords
cells
cell
isolated
culture
isolated cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014550544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503918A (ja
JP2015503918A5 (enExample
Inventor
パテル、アミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48698707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6548897(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2015503918A publication Critical patent/JP2015503918A/ja
Publication of JP2015503918A5 publication Critical patent/JP2015503918A5/ja
Application granted granted Critical
Publication of JP6548897B2 publication Critical patent/JP6548897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2014550544A 2011-12-30 2012-12-31 同種異系細胞の医療用途の誘導のための方法及び組成物並びに治療的利用 Active JP6548897B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161582070P 2011-12-30 2011-12-30
US61/582,070 2011-12-30
US201261591211P 2012-01-26 2012-01-26
US61/591,211 2012-01-26
PCT/US2012/072331 WO2013102219A1 (en) 2011-12-30 2012-12-31 Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses

Publications (3)

Publication Number Publication Date
JP2015503918A JP2015503918A (ja) 2015-02-05
JP2015503918A5 JP2015503918A5 (enExample) 2016-02-18
JP6548897B2 true JP6548897B2 (ja) 2019-07-24

Family

ID=48698707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014550544A Active JP6548897B2 (ja) 2011-12-30 2012-12-31 同種異系細胞の医療用途の誘導のための方法及び組成物並びに治療的利用

Country Status (12)

Country Link
US (7) US9803176B2 (enExample)
EP (2) EP2798058B1 (enExample)
JP (1) JP6548897B2 (enExample)
CA (2) CA3113484A1 (enExample)
DK (1) DK3321355T3 (enExample)
ES (2) ES2890126T3 (enExample)
HR (1) HRP20211373T1 (enExample)
HU (1) HUE056817T2 (enExample)
PL (1) PL3321355T3 (enExample)
PT (1) PT3321355T (enExample)
SI (1) SI3321355T1 (enExample)
WO (1) WO2013102219A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623940C (en) 2005-09-27 2017-01-10 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
JP6343671B2 (ja) * 2013-12-12 2018-06-13 サムスン ライフ パブリック ウェルフェア ファウンデーション トロンビンを利用した幹細胞由来のエキソソームの生成促進方法
US9919011B2 (en) 2014-03-18 2018-03-20 Samsung Life Public Welfare Foundation Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome
AU2015264025A1 (en) * 2014-05-21 2016-12-01 Mimedx Group, Inc. Micronized Wharton's jelly
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
EP3167049A4 (en) 2014-07-08 2017-11-29 MIMEDX Group Inc. Micronized wharton's jelly
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
JP2018516869A (ja) 2015-05-20 2018-06-28 ティッシュテック，インク． 上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
KR20170020273A (ko) 2015-08-12 2017-02-22 (주)차바이오텍 향상된 탯줄 유래 부착형 줄기세포, 그의 제조방법 및 용도
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
EP3474869B1 (en) * 2016-06-24 2025-04-09 Osiris Therapeutics, Inc. Human tissue derived compositions and uses thereof
KR102048228B1 (ko) 2016-12-02 2019-11-25 가톨릭대학교 산학협력단 Ｔ 세포 자극용 엑소좀 및 이의 약제학적 용도
KR101864234B1 (ko) * 2017-07-04 2018-06-04 인하대학교 산학협력단 음경해면체 유래 엑소좀을 유효성분으로 포함하는, 발기부전 예방, 개선 또는 치료용 조성물
US11285177B2 (en) 2018-01-03 2022-03-29 Globus Medical, Inc. Allografts containing viable cells and methods thereof
CN108239621B (zh) * 2018-01-24 2020-08-18 北京臻溪谷医学研究中心（有限合伙） 一种胎盘亚全能干细胞分离、扩增、冻存、复苏干细胞的方法
US20230357724A1 (en) 2019-01-16 2023-11-09 University Of Utah Research Foundation Human umbilical cord mesenchymal stem cell sheets and methods for their production
EP3911734A4 (en) * 2019-01-16 2022-11-09 University of Utah Research Foundation USING MESENCHYMATOUS STEM CELL SHEETS TO PREVENT UTERINE SCARS
US20230338428A1 (en) * 2020-09-08 2023-10-26 Amit Patel Allogenic umbilical cord stem cells for treating severe respiratory conditions
US20230057957A1 (en) * 2021-08-23 2023-02-23 Therapeutic Solutions International, Inc. Umbilical cord mesenchymal stem cells for treatment of chronic obstructive pulmonary disease and lung degeneration
US20230293598A1 (en) * 2022-03-15 2023-09-21 Narkeshyo LLC Prevention of radiation exposure associated pathology by treatment with umbilical cord derived regenerative cells
US20240003871A1 (en) * 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
EP1082410B1 (en) 1998-05-29 2007-08-01 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
US20030161818A1 (en) 2002-02-25 2003-08-28 Kansas State University Research Foundation Cultures, products and methods using stem cells
JP4790592B2 (ja) 2003-02-11 2011-10-12 ダビース，ジヨン・イー ヒト臍帯のウォートンジェリーからの前駆細胞
CA2530421C (en) 2003-06-27 2015-04-21 Ethicon, Incorporated Repair and regeneration of ocular tissue using postpartum-derived cells
NZ553695A (en) * 2004-08-16 2009-10-30 Cellres Corp Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
WO2007106089A1 (en) 2006-03-14 2007-09-20 Spherical Dynamics, Inc. System for and method for psychological assessment
HRP20130765T1 (hr) * 2007-02-12 2013-10-25 Anthrogenesis Corporation Lijeäśenje protuupalnih bolesti putem matiäśnih stanica posteljice
PT103843B (pt) 2007-10-04 2008-08-12 Medinfar Produtos Farmaceutico Método de isolamento de células precursoras a partir do cordão umbilical humano
WO2010060031A1 (en) * 2008-11-21 2010-05-27 Anthrogenesis Corporation Treatment of diseases, disorders or conditions of the lung using placental cells
CN101748096B (zh) * 2008-12-17 2013-03-13 北京汉氏联合生物技术有限公司 亚全能干细胞、其制备方法及其用途
CA2756670A1 (en) 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
IN2012DN02532A (enExample) * 2009-09-23 2015-08-28 Davinci Bioscineces Llc
CN101890050B (zh) * 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
EP2540819A1 (en) 2011-06-27 2013-01-02 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) Method for cultivating cells in platelet-lysate-containing medium
US20210355437A1 (en) 2015-09-02 2021-11-18 Restem Llc Factor rich product from umbilical cord mesenchymal stem cells

Also Published As

Publication number Publication date
US20130216505A1 (en) 2013-08-22
ES2890126T3 (es) 2022-01-17
US20220041992A1 (en) 2022-02-10
SI3321355T1 (sl) 2021-11-30
CA3113484A1 (en) 2013-07-04
US9803176B2 (en) 2017-10-31
ES2656614T3 (es) 2018-02-27
CA2862661C (en) 2021-05-25
PT3321355T (pt) 2021-09-28
JP2015503918A (ja) 2015-02-05
EP3321355B1 (en) 2021-08-25
US20220251515A1 (en) 2022-08-11
EP2798058A1 (en) 2014-11-05
PL3321355T3 (pl) 2021-12-27
EP2798058A4 (en) 2015-05-20
EP3321355A1 (en) 2018-05-16
US12441986B2 (en) 2025-10-14
DK3321355T3 (da) 2021-11-08
WO2013102219A1 (en) 2013-07-04
CA2862661A1 (en) 2013-07-04
HRP20211373T1 (hr) 2021-11-26
EP2798058B1 (en) 2017-10-18
US20220251514A1 (en) 2022-08-11
US20220251513A1 (en) 2022-08-11
HUE056817T2 (hu) 2022-03-28
US20190218519A1 (en) 2019-07-18
US20250346865A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
US12441986B2 (en) Methods and compositions for the clinical derivation of a stem cell and therapeutic uses
CN101748096B (zh) 亚全能干细胞、其制备方法及其用途
JP4336821B2 (ja) 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導
CN101272798B (zh) 基因修饰以表达自杀基因的骨髓间充质干细胞在制造用于治疗癌症的药物中的用途
US20150125950A1 (en) Umbilical cord mesenchymal stem cell exosomes
US20200377859A1 (en) Umbilical cord mesenchymal stem cells (mscs) and culture method and application thereof
JP2025128196A (ja) 線維芽細胞再生細胞
JP2009536163A (ja) 免疫学的寛容および調節性前駆細胞
JP6883904B2 (ja) 線維芽細胞の製造方法及びｇ−ｃｓｆ陽性線維芽細胞集団
JP2017530977A (ja) 肺高血圧症の治療剤としての心筋球由来細胞（ｃｄｃ）
Melgar-Lesmes et al. Implantation of healthy matrix-embedded endothelial cells rescues dysfunctional endothelium and ischaemic tissue in liver engraftment
CN101657536A (zh) 软骨细胞制备方法
Yang et al. Cardiac myocyte progenitors from adult hearts for myocardial regenerative therapy
JP7506905B2 (ja) 添加剤
JPWO2018003997A1 (ja) 臓器線維症の予防または治療剤
EP3533801A1 (en) Synoviolin expression inhibitor containing mesenchymal stem cell or culture supernatant thereof
KR20160144780A (ko) 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법
US20100226894A1 (en) Mobilization of a complete cells mixture with embryonic like stem cells from the peripheral blood
JP7044429B1 (ja) 腫瘍を縮小、又は消失させるための組成物
WO2024128224A1 (ja) 間葉系幹細胞の脂肪細胞への分化能を増幅させるための組成物
Monteiro et al. Clinical and radiographic characterization of xenotransplantation of rat bonemarrow-derived mesenchymal stem cells for repair of radial defects of rabbit
WO2016158670A1 (ja) 脱分化脂肪細胞を有効成分とする血管再生療法用組成物
HL 3rd EACTS Meeting on Cardiac and Pulmonary Regeneration Berlin-Brandenburgische Akademie, Berlin, Germany, 14–15 December 2012
KR20210046196A (ko) 말과동물 양막-유래 중간엽 줄기세포 및 이의 용도
Sarson Shortened Poly-N-Acetyl Glucosamine (sNAG) Nanofibers Induce Rapid Vascular Assembly in 3-Dimensional Microtissue Spheroids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180320

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190626

R150 Certificate of patent or registration of utility model

Ref document number: 6548897

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250